共 6 条
[3]
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer:: Low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C
[J].
EUROPEAN UROLOGY,
2007, 52 (05)
:1398-1406
[5]
ZBAR B, 1974, CANCER, V34, P1532, DOI 10.1002/1097-0142(197410)34:8+<1532::AID-CNCR2820340827>3.0.CO
[6]
2-H